EP1917036A2 - Intermolekularer assoziationskomplex eines trägers und eines wirkstoffs - Google Patents

Intermolekularer assoziationskomplex eines trägers und eines wirkstoffs

Info

Publication number
EP1917036A2
EP1917036A2 EP06777885A EP06777885A EP1917036A2 EP 1917036 A2 EP1917036 A2 EP 1917036A2 EP 06777885 A EP06777885 A EP 06777885A EP 06777885 A EP06777885 A EP 06777885A EP 1917036 A2 EP1917036 A2 EP 1917036A2
Authority
EP
European Patent Office
Prior art keywords
active ingredient
chosen
intermolecular association
combinations
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06777885A
Other languages
English (en)
French (fr)
Inventor
Sabrina Consola
Muriel Blanzat
Isabelle Rico-Lattes
Emile Perez
Pascal Bordat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Pierre Fabre Dermo Cosmetique SA
Universite de Toulouse
Original Assignee
Centre National de la Recherche Scientifique CNRS
Pierre Fabre Dermo Cosmetique SA
Universite Toulouse III Paul Sabatier
Universite de Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Pierre Fabre Dermo Cosmetique SA, Universite Toulouse III Paul Sabatier, Universite de Toulouse filed Critical Centre National de la Recherche Scientifique CNRS
Publication of EP1917036A2 publication Critical patent/EP1917036A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the active ingredient may be encapsulated within a phospholipid vesicle or immobilized in microspheres of biodegradable polymer.
  • the delivery of active ingredients through the skin has many advantages. Variable rates of absorption and metabolism associated with oral therapy are avoided, as well as possible gastrointestinal irritation.
  • the delivery of the active ingredient transcutaneously also allows better control of blood levels.
  • the skin has a complex structure and molecules administered transcutaneously or topically must first cross a barrier formed by the stratum corneum before reaching the blood stream.
  • the stratum corneum consists of a dense and highly keratinized layer with an average thickness of 10-15 microns.
  • the high degree of keratinization, as well as the compact assembly of the cells can constitute a virtually impermeable barrier to the passage of an active ingredient.
  • the rate of permeabilization through the skin is extremely slow.
  • Many additives can be used to increase the rate of penetration of the active ingredient through the skin.
  • Most of the compounds are administered at the same time as the drug (in some cases the skin may be pretreated with a permeabilizer) so as to increase the permeability of the stratum corneum and thereby increase the penetration of the active ingredient through the skin.
  • the permeability of many therapeutic agents can be improved by these permeabilizers.
  • Several additives are able to promote the transport of active ingredients through the skin according to several mechanisms, the most important of which are:
  • Permeabilization agents can be classified into different categories. Solvents such as alcohols, methyl sulphoxides and polyols increase the solubility which increases the skin passage. In addition, some solvents such as dimethylsulfoxide (DMSO) or ethanol, will extract the lipids and make the stratum corneum more permeable. Oleic acid and isopropyl myristate are typical examples of permeabilization agents that disrupt the stratum corneum by intercalating into the lipid structures. This emollient effect thus increases the diffusion coefficient of the active ingredient. Also, ionic surfactants or DMSO interact with the keratin of corneocytes, which deploys the structure of the protein and increases the diffusion coefficient.
  • DMSO dimethylsulfoxide
  • ethanol ethanol
  • Oleic acid and isopropyl myristate are typical examples of permeabilization agents that disrupt the stratum corneum by intercalating into the lipid structures. This emollient effect thus increases the diffusion coefficient of the
  • the present invention describes an original strategy of actively involving the active ingredient in its own transport. This intermolecular association will aim to protect, solubilize and convey the drug to the action site.
  • it is proposed to associate, by simple electrostatic acid / base interaction, an acidic active ingredient with a biocompatible basic amphiphilic molecule. This combination can be stabilized by hydrophobic type interactions between the active ingredient and the amphiphilic molecule.
  • this invention relates to formulation applications, such as solubilization, transport, protection and transcutaneous diffusion of an active ingredient. Indeed, this amphiphilic molecule may also act as a permeabilization agent for transcutaneous transport.
  • the invention relates to the combination of a biocompatible basic transporter with an active ingredient comprising one or more acid functional groups.
  • This intermolecular association leads to a new amphiphilic species corresponding to the formation of an acid / base pair bound by electrostatic interactions and stabilized by Van der Waals interactions between the hydrophobic parts of the two constituents.
  • the amphiphilic complex thus formed by association leads, according to its concentration in water as well as the nature of the active ingredient (volume, hydrophobicity), to a set of self-assembled structures such as micelles or vesicles.
  • the objects thus formed can also be used for the self-transport of the active ingredient.
  • the present invention thus relates to an association complex formed between an amphiphilic molecule and an active ingredient.
  • the object of the present invention is an intermolecular association complex of formula (I) of an amphiphilic transporter and an active ingredient " ZY:
  • S represents a carbohydrate residue selected from the group consisting of monosaccharides, disaccharides, polysaccharides, polyols and combinations of these residues,
  • X represents a C 1 -C 12 aliphatic residue chosen from alkyl, alkene, alkyne, linear or branched, or an ethylene oxide or propylene oxide unit having a degree of polymerization of between 1 and 10, as well as all the combinations of these residues,
  • n 0 or l
  • R 1 represents H
  • R 2 , R 3 independently represent a hydrogen atom or a linear or branched C1-C20 or perfluorinated hydrocarbon chain, as well as all the combinations of these substituents, and in which the active ingredient
  • Y carrying the therapeutic or pro-therapeutic activity, chosen from the group comprising anti-inflammatories, antibiotics, polyunsaturated fatty chain, vitamins or pro-vitamins and a residue
  • Z acid selected from the group consisting of carboxylates, sulfates sulfonates, phosphates, phosphonates or phosphinates.
  • the present invention also relates to the use of a complex as defined above to protect, solubilize and / or convey an active ingredient.
  • the invention also relates to the use of a complex as defined above for the manufacture of a medicament intended for topical or transcutaneous administration.
  • the transporter is selected from biocompatible amphiphilic molecules having one or more basic functions.
  • amphiphilic transporter will be chosen from carbohydrate derivatives having one or more hydrophobic chains, as well as one or more basic functions capable of interacting electrostatically with the active acidic principle.
  • This amphiphilic carrier has the general formula (II):
  • S represents a carbohydrate residue selected from the group consisting of monosaccharides, disaccharides, polysaccharides, polyols and combinations of these residues,
  • X represents a C 1 -C 12 aliphatic residue, alkene, alkyne, linear or branched, or an ethylene oxide or propylene oxide unit with a degree of polymerization of between 1 and 10, as well as all the combinations of these residues,
  • n 0 or 1
  • R 1 represents H
  • R 2 and R 3 independently represent a hydrogen atom or a linear or branched C1-C20 or perfluorinated hydrocarbon chain, as well as all the combinations of these substituents.
  • the amphiphilic transporter will advantageously be chosen from sugar-chain and long-chain amino surfactants, such as N- alkylamino-1-deoxylactitols having a chain with 12 or 16 carbon atoms, which will be named respectively Lhydl2 and Lhydl ⁇ .
  • N-alkylamino-1-deoxylactitols is as follows:
  • the active ingredient will preferably be chosen from non-steroidal anti-inflammatory drugs (NSAIDs) carrying an acid function, such as ketoprofen, ibuprofen or indomethacin.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • the complexes according to the present invention may advantageously be used to solubilize and transport by acid / base combination polyunsaturated fatty acids (PUFAs) such as linoleic acid or linolenic acid.
  • PUFAs polyunsaturated fatty acids
  • the intermolecular combination (stoichiometric or not) will be formed by simple contact in water or in another solvent, the amphiphilic molecule in its basic form with the active ingredient in its acid form .
  • the invention therefore relates to a combination by simple neutralization acid / base between the amphiphilic transporter in its basic form and the active ingredient in its acid form.
  • the invention also relates to a process for preparing the present complexes.
  • the stoichiometric mixture of amphiphilic carrier and active principle is advantageously reacted by heating it at a temperature between room temperature and the boiling point of the solvent at atmospheric pressure, and for a duration of 1 to 72 hours. .
  • the final mixture is freed from its water, preferably filtered and freeze-dried.
  • the reactants and the solvent are chosen as follows:
  • the basic carrier is Lhydl2 or Lhydl ⁇
  • the active principle is indomethacin, ibuprofen, ketoprofen or linoleic acid.
  • the solvent is water or methanol.
  • the association constitutes a new amphiphilic species which forms aggregates with a diameter of less than 10 nm from a CAC of 10 "3 M.
  • the association constitutes a new amphiphilic species that forms aggregates with a diameter of 50 nm from a CAC of 4.5 ⁇ 10 ⁇ M.
  • formula B preparation of a 2.5% combination of indomethacin in aqueous solution
  • B1 indomethacin combination with Lhydl ⁇
  • B2 indomethacin combination with Lhydl2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP06777885A 2005-07-22 2006-07-21 Intermolekularer assoziationskomplex eines trägers und eines wirkstoffs Withdrawn EP1917036A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0507856A FR2888752B1 (fr) 2005-07-22 2005-07-22 Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
PCT/EP2006/064502 WO2007010032A2 (fr) 2005-07-22 2006-07-21 Complexe d'association intermoleculaire d'un transporteur, preferablement un n-alkylamino-1-deoxylactitol, et d'un principe actif

Publications (1)

Publication Number Publication Date
EP1917036A2 true EP1917036A2 (de) 2008-05-07

Family

ID=36218212

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06777885A Withdrawn EP1917036A2 (de) 2005-07-22 2006-07-21 Intermolekularer assoziationskomplex eines trägers und eines wirkstoffs

Country Status (7)

Country Link
US (1) US20090137656A1 (de)
EP (1) EP1917036A2 (de)
JP (1) JP2009502764A (de)
BR (1) BRPI0613671A2 (de)
CA (1) CA2616091A1 (de)
FR (1) FR2888752B1 (de)
WO (1) WO2007010032A2 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
FR2553099B1 (fr) * 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
FR2729959B1 (fr) * 1995-01-30 1997-03-21 Stepan Europe Lactylamines et applications pharmaceutiques
DE19932197A1 (de) * 1999-07-09 2001-01-18 Neudecker Birgit Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung
US7655768B2 (en) * 2004-08-26 2010-02-02 Nippon Shinyaku Co., Ltd. Galactose derivative, drug carrier and medicinal composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007010032A2 *

Also Published As

Publication number Publication date
FR2888752B1 (fr) 2007-10-05
US20090137656A1 (en) 2009-05-28
JP2009502764A (ja) 2009-01-29
BRPI0613671A2 (pt) 2011-01-25
WO2007010032A2 (fr) 2007-01-25
FR2888752A1 (fr) 2007-01-26
WO2007010032A3 (fr) 2008-06-19
CA2616091A1 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
FR2808691A1 (fr) Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
EP2854793B1 (de) Lipidnanokapseln mit einem retinoid, nanodispersion und zusammensetzung damit, verfahren zur herstellung davon und verwendung davon in der dermatologie
WO1993015708A1 (fr) Composition cosmetique et/ou pharmaceutique contenant une dispersion de vesicules lipidiques, procede de preparation de ladite dispersion et dispersion de vesicules lipidiques
EP3076944A1 (de) Lipidmikrokapseln, vorzugsweise mit einem lipophilen wirkstoff und zusammensetzung damit, verfahren zur herstellung und verwendung in der dermatologie und kosmetik
EP2854775A1 (de) Mikrokapseln mt retinoiden, verfahren zur herstellung davon und pharmazeutische zusammensetzungen damit
EP0862423A1 (de) Oral anzuwendende arzneizubereitung
WO2018181538A1 (ja) ナノディスクとその製造方法
CA2649124A1 (fr) Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations
EP1035846A2 (de) Verwendung von nmifa als entzündungshemmer in oberflächlichem saugetier-gewebe
FR2958647A1 (fr) Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
WO2013178758A1 (fr) Compositions pharmaceutiques topiques de type émulsion h/e contenant un rétinoïde
FR2879459A1 (fr) Composition comprenant de l'adapalene solubilise avec des cyclodextrines
FR3110427A1 (fr) Conjugué terpenique de couplage
CA2755171A1 (fr) Compositions comprenant au moins un complexe compose d'un derive d'acide naphtoique et d'au moins une cyclodextrine et leurs utilisations
CA2323717A1 (fr) Procede pour limiter la penetration dans la peau et/ou les fibres keratiniques d'un agent cosmetique et/ou pharmaceutique actif
EP1917036A2 (de) Intermolekularer assoziationskomplex eines trägers und eines wirkstoffs
EP2482853B1 (de) Kooperative übermittlung von basischen wirkstoffen durch amphiphile säuremoleküle
CA2611883A1 (fr) Procede de solubilisation du metronidazole
JP2006249010A (ja) 皮膚外用剤
WO2013026989A2 (fr) Liposome comprenant au moins un derive de cholesterol
EP3302421B1 (de) Zusammensetzungen mit mindestens einem dispergierten wirkstoff und lipid-mikrokapseln
FR3119325A1 (fr) Compositions liposomales orales
EP4713026A1 (de) Langwirkende schmerzlindernde formulierung
EP2678024A1 (de) Kutane pharmazeutische zusammensetzungen zur topischen behandlung von atopischer dermatitis des hundes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080117

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20080619

17Q First examination report despatched

Effective date: 20090512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111220